Alex Goldberg

Auxilium Pharmaceuticals Inc. (NASDAQ:AUXL) and Athenahealth, Inc. (NASDAQ:ATHN) Added to Equity Profile Report's NASDAQ Gainers Watch List.

 
Repost This

Wilmington, DE -- (SBWIRE) -- 02/18/2014 -- Equity Profile Report expands its NASDAQ Gainers Weekly Watch List adding Auxilium Pharmaceuticals Inc. (NASDAQ:AUXL) and athenahealth, Inc. (NASDAQ:ATHN).

Auxilium Pharmaceuticals Inc. (NASDAQ:AUXL) a specialty biopharmaceutical company that together with its subsidiaries, focuses on developing and marketing pharmaceutical products in urology and sexual health worldwide is currently up (+5.47%) on 1,418,207 shares traded. Auxilium Pharmaceuticals Inc. (NASDAQ:AUXL) is currently up (+105.12%) from its recent 52-week low which has prompted Equity Profile Report to add the stock to their NASDAQ Gainers Watch List.

Click Here to find out what other Investors are saying about Auxilium Pharmaceuticals Inc. (NASDAQ:AUXL)

athenahealth, Inc. (NASDAQ:ATHN) a business services company that provides ongoing billing, clinical-related, and other related services to medical group practices primarily in the United States is currently up (+2.60%) on 537,932 shares traded after AthenaHealth has been upgraded by Robert W. Baird. athenahealth, Inc. (NASDAQ:ATHN) is currently up (+141.91%) from its recent 52-week low which has prompted Equity Profile Report to add the stock to their NASDAQ Gainers Watch List.

Click Here to find out what other Investors are saying about athenahealth, Inc. (NASDAQ:ATHN)

Equityprofilereport.com monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities.

Through a vast network of IR professionals Equityprofilereport.com is often aware of several large investor awareness campaigns being deployed.

Timing is important when trading Small Caps and Penny Stocks.

Simply sign up for free and start receiving exclusive alerts.

Subscribe Here: http://www.Equityprofilereport.com

Disclosure
Equityprofilereport.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit Equityprofilereport.com website, for complete risks and disclosures.

Contact Info:
Equity Profile Report
editor@Equityprofilereport.com